CO5261609A1 - Inhibidores de caspasa y usos de estos - Google Patents
Inhibidores de caspasa y usos de estosInfo
- Publication number
- CO5261609A1 CO5261609A1 CO00093694A CO00093694A CO5261609A1 CO 5261609 A1 CO5261609 A1 CO 5261609A1 CO 00093694 A CO00093694 A CO 00093694A CO 00093694 A CO00093694 A CO 00093694A CO 5261609 A1 CO5261609 A1 CO 5261609A1
- Authority
- CO
- Colombia
- Prior art keywords
- ring
- substituted
- nitrogen
- group
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
Abstract
Un compuesto de fórmula (I): <EMI FILE="00093694_1" ID="1" IMF=JPEG >En donde R1 es hidrógeno, CN, CHN2, R, o -CH2Y, R es un grupo alifático, un grupo alifático sustituido, un grupo arilo, un grupo arilo sustituido, un grupo aralquilo sustituido, un grupo heterocíclico no aromático o un grupo heterocíclico no aromático sustituido, Y es un grupo saliente electronegativo o -OR, -SR, -OC=O (R), o -OPO (R8) (R9); R8 y R9 son independientemente seleccionados de R u OR; R2 es CO2H, CH2CO2H, o ésteres, o amidas isoésteres de estos; R3 es hidrógeno o un alquilo de cadena recta o ramificada C1-6; El anillo A contiene de cero a dos dobles enlaces y está opcionalmente fusionado a un anillo de 5 a 7 miembros saturado o insaturado que contiene de 0 a 3 heteroátomos; X1 y X3 en el anillo son independientemente seleccionados de nitrógeno o carbono y X2 se selecciona de un enlace de valencia, oxígeno, azufre, nitrógeno o carbono, en donde cualquier X con una valencia adecuada puede llevar un sustituyente; Cada carbono con valencia adecuada en el anillo A que incluye un anillo fusionado si está presente, es independientemente sustituido mediante hidrógeno, halo, R, OR, SR, OH, NO2, CN, NH2, NHR, N(R)2, NHCOR, NHCONHR, NHCON(R)2, NRCOR, NH CO2R, CO2R, CO2H, COR, CONHR, CON(R)2, S(O)2R, SONH2, S(O)R, SO2NHR, NHS(O)2R, =S, =NNHR, =NNR2, =N-OR, =NNHCOR, =NNHCO2R, =NNHS2R, o =NR; cada nitrógeno sustituible en el anillo A está sustituido mediante hidrógeno, R, COR, S(O)2R, o C02R,Con la condición de que cuando X3 sea un carbono, un sustituyente sobre X3 se une mediante un átomo diferente de nitrógeno, Y adicionalmente con la condición que por lo menos un X en el anillo A sea un nitrógeno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16981299P | 1999-12-08 | 1999-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261609A1 true CO5261609A1 (es) | 2003-03-31 |
Family
ID=22617272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00093694A CO5261609A1 (es) | 1999-12-08 | 2000-12-07 | Inhibidores de caspasa y usos de estos |
Country Status (24)
Country | Link |
---|---|
US (4) | US7517987B2 (es) |
EP (4) | EP2308846A3 (es) |
JP (3) | JP5021131B2 (es) |
KR (3) | KR100904697B1 (es) |
CN (2) | CN101348455A (es) |
AP (1) | AP2002002535A0 (es) |
AR (1) | AR026748A1 (es) |
AU (3) | AU2428301A (es) |
BR (1) | BR0016282A (es) |
CA (2) | CA2393710C (es) |
CO (1) | CO5261609A1 (es) |
CZ (1) | CZ20021970A3 (es) |
EA (1) | EA200200645A1 (es) |
HU (1) | HUP0300782A3 (es) |
IL (1) | IL150077A0 (es) |
IS (1) | IS6411A (es) |
MX (1) | MXPA02005779A (es) |
NO (2) | NO324776B1 (es) |
NZ (2) | NZ530485A (es) |
PL (1) | PL356066A1 (es) |
SK (1) | SK8072002A3 (es) |
TW (1) | TWI275586B (es) |
WO (1) | WO2001042216A2 (es) |
ZA (1) | ZA200204390B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541237A (ja) | 1999-04-09 | 2002-12-03 | サイトビア インコーポレイテッド | カスパーゼインヒビターおよびその使用 |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
US6495522B1 (en) | 1999-08-27 | 2002-12-17 | Cytovia, Inc. | Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
AR026748A1 (es) * | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
WO2002094263A2 (en) * | 2001-05-23 | 2002-11-28 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
WO2003088917A2 (en) * | 2002-04-19 | 2003-10-30 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
WO2004002961A1 (en) * | 2002-06-28 | 2004-01-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
TW200500343A (en) * | 2002-12-20 | 2005-01-01 | Vertex Pharma | Caspase inhibitors and uses thereof |
PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
WO2004113305A2 (en) * | 2003-06-16 | 2004-12-29 | Vertex Pharmaceuticals Incorporated | Diamino substituted quinazoline derivatives as promoters of smn2 |
JP4898658B2 (ja) | 2004-03-12 | 2012-03-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体 |
CA2566362C (en) * | 2004-05-15 | 2013-09-10 | Vertex Pharmaceuticals Incorporated | Treating seizures using ice inhibitors |
CN1980658A (zh) | 2004-05-27 | 2007-06-13 | 沃泰克斯药物股份有限公司 | 治疗自身炎性疾病的ice抑制剂 |
WO2006057961A1 (en) | 2004-11-24 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
NZ566022A (en) | 2005-07-28 | 2011-04-29 | Vertex Pharma | Caspase inhibitor prodrugs |
WO2007104034A2 (en) * | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
TW200823225A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New compounds |
EP2091947A2 (en) * | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
DK2288615T3 (en) | 2008-05-21 | 2017-09-04 | Genesis Tech Ltd | SELECTIVE CASPASE INHIBITORS AND APPLICATIONS THEREOF |
WO2010017408A1 (en) * | 2008-08-06 | 2010-02-11 | The Buck Institute For Age Research | Caspase inhibitors and uses thereof |
WO2010039534A2 (en) * | 2008-09-23 | 2010-04-08 | Georgetown University | Viral and fungal inhibitors |
WO2010039545A2 (en) | 2008-09-23 | 2010-04-08 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
US9045524B2 (en) | 2009-05-21 | 2015-06-02 | Novagenesis Foundation | Selective caspase inhibitors and uses thereof |
WO2010138585A1 (en) * | 2009-05-29 | 2010-12-02 | Merck Sharp & Dohme Corp. | Pyrimidinones as pde10 inhibitors |
EP2470336B1 (en) | 2009-08-25 | 2013-08-14 | Lasermax Roll Systems, Inc. | System and method for inline cutting and stacking of sheets for formation of books |
US8882099B2 (en) | 2009-08-25 | 2014-11-11 | Lasermax Roll Systems, Inc. | System and method for inline cutting and stacking of sheets for formation of books |
US9365612B2 (en) | 2010-01-29 | 2016-06-14 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Caspase inhibitors |
WO2012061786A1 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
ES2665301T3 (es) | 2011-04-15 | 2018-04-25 | Genesis Technologies Limited | Inhibidores selectivos de cisteína proreasa y usos de los mismos |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
WO2013025897A1 (en) | 2011-08-16 | 2013-02-21 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
WO2014160592A2 (en) * | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
CN110177774B (zh) * | 2017-01-23 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
CN106749045B (zh) * | 2017-03-03 | 2020-02-14 | 上海交通大学 | 一种d-氨基酸氧化酶抑制剂及其制法和应用 |
CN111433176B (zh) * | 2017-10-04 | 2023-08-29 | 巴特尔纪念研究院 | 用于选择性表征异生物质代谢中涉及的酶的探针以及制造和使用该探针的方法 |
CN115551494A (zh) * | 2020-03-13 | 2022-12-30 | 纽约市哥伦比亚大学理事会 | Gpx4化合物和组合物以及使用它们的治疗方法 |
JP2023537012A (ja) * | 2020-08-05 | 2023-08-30 | エルジー・ケム・リミテッド | 変形性関節症の緩和又は治療するためのカスパーゼ阻害剤の使用 |
KR102670554B1 (ko) * | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
WO2024073426A1 (en) * | 2022-09-26 | 2024-04-04 | Edgewise Therapeutics, Inc. | 1,4-dihydroquinazolinone compounds and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
FR2582514B1 (fr) | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
DE69320176T2 (de) | 1992-02-21 | 1999-04-08 | Merck & Co Inc | Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms |
US5714484A (en) * | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
US5618792A (en) * | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
CA2217850A1 (en) * | 1995-05-10 | 1996-11-14 | Chirotech Technology Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use |
US6252076B1 (en) * | 1996-05-04 | 2001-06-26 | Yuhan Corporation | Process for preparation of pyrimidine derivatives |
DK0946502T3 (da) * | 1996-10-11 | 2003-04-07 | Abbott Gmbh & Co Kg | Sulfonamidinhibitorer for det interleukin-1beta-omdannende enzym |
KR20000049048A (ko) * | 1996-10-11 | 2000-07-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인터루킨-1β 전환 효소의 아스파르테이트 에스테르 억제제 |
US6063794A (en) * | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
WO1998018781A2 (en) * | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
NZ515249A (en) * | 1999-05-07 | 2004-07-30 | Texas Biotechnology Corp | Propanoic acid derivatives that inhibit the binding of integrin alpha4-beta1 to its receptors |
US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
RU2263109C2 (ru) | 1999-05-07 | 2005-10-27 | Тексэс Байотекнолоджи Копэрейшн | ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО |
AR026748A1 (es) * | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
WO2003068242A1 (en) * | 2002-02-11 | 2003-08-21 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
WO2003088917A2 (en) * | 2002-04-19 | 2003-10-30 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
-
2000
- 2000-12-06 AR ARP000106476A patent/AR026748A1/es unknown
- 2000-12-07 TW TWCASPASEIA patent/TWI275586B/zh not_active IP Right Cessation
- 2000-12-07 CO CO00093694A patent/CO5261609A1/es not_active Application Discontinuation
- 2000-12-08 CZ CZ20021970A patent/CZ20021970A3/cs unknown
- 2000-12-08 SK SK807-2002A patent/SK8072002A3/sk not_active Application Discontinuation
- 2000-12-08 CN CNA2008101443995A patent/CN101348455A/zh active Pending
- 2000-12-08 AP APAP/P/2002/002535A patent/AP2002002535A0/en unknown
- 2000-12-08 EP EP10196409A patent/EP2308846A3/en not_active Withdrawn
- 2000-12-08 JP JP2001543517A patent/JP5021131B2/ja not_active Expired - Fee Related
- 2000-12-08 AU AU24283/01A patent/AU2428301A/en not_active Abandoned
- 2000-12-08 PL PL00356066A patent/PL356066A1/xx not_active Application Discontinuation
- 2000-12-08 MX MXPA02005779A patent/MXPA02005779A/es active IP Right Grant
- 2000-12-08 NZ NZ530485A patent/NZ530485A/en unknown
- 2000-12-08 EP EP10196401A patent/EP2308844A3/en not_active Withdrawn
- 2000-12-08 WO PCT/US2000/033260 patent/WO2001042216A2/en active IP Right Grant
- 2000-12-08 EP EP00988026A patent/EP1244626A2/en not_active Withdrawn
- 2000-12-08 HU HU0300782A patent/HUP0300782A3/hu unknown
- 2000-12-08 KR KR1020027007337A patent/KR100904697B1/ko not_active IP Right Cessation
- 2000-12-08 CA CA2393710A patent/CA2393710C/en not_active Expired - Fee Related
- 2000-12-08 CA CA2733434A patent/CA2733434A1/en not_active Abandoned
- 2000-12-08 IL IL15007700A patent/IL150077A0/xx unknown
- 2000-12-08 BR BR0016282-5A patent/BR0016282A/pt not_active Application Discontinuation
- 2000-12-08 EA EA200200645A patent/EA200200645A1/ru unknown
- 2000-12-08 CN CNB008182558A patent/CN100415718C/zh not_active Expired - Fee Related
- 2000-12-08 NZ NZ519424A patent/NZ519424A/en not_active IP Right Cessation
- 2000-12-08 EP EP10196405A patent/EP2308845A3/en not_active Withdrawn
-
2002
- 2002-05-31 ZA ZA200204390A patent/ZA200204390B/xx unknown
- 2002-06-05 NO NO20022656A patent/NO324776B1/no not_active IP Right Cessation
- 2002-06-06 IS IS6411A patent/IS6411A/is unknown
- 2002-06-10 US US10/166,437 patent/US7517987B2/en not_active Expired - Fee Related
-
2006
- 2006-10-10 AU AU2006225317A patent/AU2006225317A1/en not_active Abandoned
-
2007
- 2007-09-19 NO NO20074773A patent/NO20074773L/no not_active Application Discontinuation
- 2007-12-05 JP JP2007315252A patent/JP2008101019A/ja not_active Withdrawn
-
2008
- 2008-02-18 KR KR1020087003852A patent/KR100910195B1/ko not_active IP Right Cessation
-
2009
- 2009-01-26 US US12/359,749 patent/US7906650B2/en not_active Expired - Fee Related
- 2009-03-12 KR KR1020097005203A patent/KR100919654B1/ko not_active IP Right Cessation
-
2010
- 2010-05-21 AU AU2010202075A patent/AU2010202075B2/en not_active Ceased
-
2011
- 2011-02-08 US US13/022,820 patent/US8093392B2/en not_active Expired - Fee Related
- 2011-10-25 JP JP2011234386A patent/JP2012021032A/ja not_active Withdrawn
- 2011-12-01 US US13/309,117 patent/US8288537B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261609A1 (es) | Inhibidores de caspasa y usos de estos | |
MX172089B (es) | Composicion mejorada de concentrado de aditivo | |
IL80172A0 (en) | Sulphonylphenylalkylamines,processes for the preparation thereof and pharmaceutical compositions containing them | |
DE60209497D1 (de) | Schmierölzusammensetzung enthaltend ein gemisch aus carboxylsäuren und aminen als rostschutzmittel | |
PT90805A (pt) | Processo para a preparacao de 1-indolilalquil-4-(piridinil substituido)-piperazinas e de composicoes farmaceuticas que as contem | |
AR076896A2 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados | |
HUP9700997A1 (hu) | Benzimidazolszármazékok és e vegyületeket tartalmazó, antihisztamin hatású gyógyászati készítmények | |
HK1006967A1 (en) | Nitric esters of derivatives of the 2-(2,6-di-halophenylamino)phenylacetic acid and process for their preparation | |
CO4950561A1 (es) | Derivados de ergolina | |
ATE56946T1 (de) | Amino-propanol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte. | |
DE69615555D1 (de) | 6-carboxamido-dihydropyran-derivate | |
AR024918A1 (es) | Derivados de ciclobuteno, su preparacion y sus usos terapeuticos. | |
MX168361B (es) | Compuestos que contienen boro y azufre y concentrados aditivos y aceites lubricantes que los contienen | |
AR006991A1 (es) | Analogo hidrosoluble de 20(s)- camptotecina, una composicion farmaceutica que los contiene, una medicina para el tratamiento del cancer, leucemia oestados relacionados con el hiv, el uso de dichos compuestos y un procedimiento para su preparacion | |
ES8205762A1 (es) | Procedimiento para la preparacion de oximas de acidos piru- vicos | |
ES2196197T3 (es) | Derivados de benzamida con propiedades inhibidoras de trombina. | |
AR247550A1 (es) | Un procedimiento para la preparacion de nuevas carboxamidas aromaticas | |
DE59007487D1 (de) | Hydroxyalkancarbonsäure-derivate und deren verwendung. | |
ATE477263T1 (de) | Zusammensetzung enthaltend ferrocen-derivate und treibstoff diese enthaltend | |
BR9809473A (pt) | Mistura fungida, e, processo para controlar fungos nocivos | |
EA200001107A1 (ru) | ПРОИЗВОДНЫЕ ОКТАГИДРО-6,10-ДИОКСО-6H-ПИРИДАЗИНО [1,2-a] [1,2] ДИАЗЕПИН-1-КАРБОНОВОЙ КИСЛОТЫ, СПОСОБ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТЕРАПЕВТИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙ | |
ES8202003A1 (es) | Un procedimiento para la preparacion de derivados de ergoli-na | |
GB1165300A (en) | Substituted Anthranilic Acid Amides | |
NZ303235A (en) | Arginine analogues as nitric oxide synthase inhibitors | |
EA200200379A2 (ru) | Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |